GB2508702A - Enalaprilat in the treatment of neurodegenerative diseases - Google Patents

Enalaprilat in the treatment of neurodegenerative diseases Download PDF

Info

Publication number
GB2508702A
GB2508702A GB1317550.0A GB201317550A GB2508702A GB 2508702 A GB2508702 A GB 2508702A GB 201317550 A GB201317550 A GB 201317550A GB 2508702 A GB2508702 A GB 2508702A
Authority
GB
United Kingdom
Prior art keywords
amyloid
beta
enalaprilat
zinc
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1317550.0A
Other languages
English (en)
Other versions
GB201317550D0 (en
Inventor
Sergey Alexandrovich Kozin
Yury Vladimirovich Mezentsev
Elena Vladimirovna Kugaevskaya
Flipp Olegovich Tsvetkov
Alexey Sergeevich Ivanov
Alexandr Ivanovich Archakov
Alexandr Alexandrovich Makarov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI
Original Assignee
FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI filed Critical FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI
Publication of GB201317550D0 publication Critical patent/GB201317550D0/en
Publication of GB2508702A publication Critical patent/GB2508702A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1317550.0A 2012-10-05 2013-10-03 Enalaprilat in the treatment of neurodegenerative diseases Withdrawn GB2508702A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012142334/15A RU2530601C2 (ru) 2012-10-05 2012-10-05 Ингибитор образования цинк-зависимых димеров бета-амилоида

Publications (2)

Publication Number Publication Date
GB201317550D0 GB201317550D0 (en) 2013-11-20
GB2508702A true GB2508702A (en) 2014-06-11

Family

ID=49630167

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1317550.0A Withdrawn GB2508702A (en) 2012-10-05 2013-10-03 Enalaprilat in the treatment of neurodegenerative diseases

Country Status (4)

Country Link
DE (1) DE102013110890A1 (ru)
FR (1) FR2996456A1 (ru)
GB (1) GB2508702A (ru)
RU (1) RU2530601C2 (ru)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481207A1 (en) * 1990-09-17 1992-04-22 E.R. SQUIBB & SONS, INC. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US20040219207A1 (en) * 2003-01-28 2004-11-04 Peter Rohnert Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
WO2005011736A1 (ja) * 2003-07-30 2005-02-10 Tohoku Techno Arch Co., Ltd. アルツハイマー病の予防および／または治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481207A1 (en) * 1990-09-17 1992-04-22 E.R. SQUIBB & SONS, INC. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US20040219207A1 (en) * 2003-01-28 2004-11-04 Peter Rohnert Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
WO2005011736A1 (ja) * 2003-07-30 2005-02-10 Tohoku Techno Arch Co., Ltd. アルツハイマー病の予防および／または治療剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Age, vol. 35, 2013, pages 441-453 *
Brain Research, vol. 1352, 2010, pages 176-186 *
European Journal of Pharmacology, vol. 200, 1991, pages 289-292 *
Journal of Research in Medical Sciences, vol. 18, 2013, S1-S5 *
The Journal of Biological Chemistry, vol. 284, No. 46, 2009, pages 31914-31920 *

Also Published As

Publication number Publication date
RU2530601C2 (ru) 2014-10-10
DE102013110890A1 (de) 2014-04-10
RU2012142334A (ru) 2014-04-10
GB201317550D0 (en) 2013-11-20
FR2996456A1 (fr) 2014-04-11

Similar Documents

Publication Publication Date Title
Henstridge et al. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Jin et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model
Morawski et al. ECM in brain aging and dementia
Zhang et al. Mechanisms of NLRP3 inflammasome activation: its role in the treatment of Alzheimer’s disease
Zhao et al. Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization
Dmytriyeva et al. The metastasis-promoting S100A4 protein confers neuroprotection in brain injury
JP2019077687A (ja) 操作された微生物標的化分子およびその使用
JP7126940B2 (ja) 補体活性のモジュレーター
Zhang et al. Cerebral mast cells participate in postoperative cognitive dysfunction by promoting astrocyte activation
TW201718023A (zh) 細胞滲透性蛋白質－抗體結合物及使用方法
TW201718024A (zh) 治療性細胞內化結合物
US20140080903A1 (en) Application of alpha-mangostin in preparation of medicaments for alzheimer's disease
Zheng et al. Engineered multifunctional zinc–organic framework-based aggregation-induced emission nanozyme for accelerating spinal cord injury recovery
CN107849125A (zh) 用于治疗靶向聚集的肽的创伤性脑损伤的方法
Rosenbaum et al. New insights into the function and pathophysiology of the ectodomain sheddase A Disintegrin And Metalloproteinase 10 (ADAM10)
Zhu et al. Mannose-coated superparamagnetic iron oxide nanozyme for preventing postoperative cognitive dysfunction
GB2508702A (en) Enalaprilat in the treatment of neurodegenerative diseases
KR20210100086A (ko) 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
ATE468350T1 (de) Peptidische verbindungen und deren ableitungen für die behandllung von menschlichen krankheiten durch hemmung der signalübertragung über wachstumfaktoren
Hill et al. The role of autophagy in hypoxia-induced radioresistance
US20210369711A1 (en) Uses of compound in preparation of drugs for treating brain glioma
Shu et al. Abnormal phosphorylation of protein tyrosine in neurodegenerative diseases
WO2012088133A1 (en) Methods for treating neurological conditions and compositions and materials therefor
Zhang et al. Nucleus-targeted nanoparticles induce autophagy of vascular endothelial cells in cervical spondylosis of vertebral artery type through PI3K/Akt/mTOR signaling pathway
Ortonne Is DRESS syndrome a single entity or within a spectrum of adverse reactions to drug?

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)